- As of June 30, 2025, WuXi Biologics supports 864 integrated projects.
- The portfolio includes 326 mAbs, 168 bispecifics & multispecifics, 225 ADCs, 80 fusion proteins, and 25 vaccines.
- Development time for mAbs from DNA to IND application is reduced to 9 months.
- The company has achieved a 98% success rate in manufacturing over 300 batches since 2022.
Recognition and Achievements
WuXi Biologics has been awarded the 2025 Global Customer Value Leadership Recognition by Frost & Sullivan. This accolade highlights the company's commitment to delivering exceptional customer value through technological innovation and operational excellence.
Project Portfolio
As of June 30, 2025, WuXi Biologics manages 864 integrated projects, making it one of the largest portfolios in the biologics industry. The portfolio includes 326 monoclonal antibodies (mAbs), 168 bispecifics and multispecifics, 225 antibody-drug conjugates (ADCs), 80 fusion proteins, and 25 vaccines.
Efficiency and Success Rates
The company has reduced the development time for mAbs from DNA to Investigational New Drug (IND) application to 9 months, with some projects completed in just 6 months. By utilizing single-use technology (SUT) and a scale-out strategy, WuXi Biologics has manufactured over 300 batches at scales ranging from 4,000 to 16,000 liters, achieving a 98% success rate since 2022.
Regulatory Compliance
WuXi Biologics' quality systems have achieved a 100% success rate in Pre-License Inspections (PLI) and have passed 44 inspections by global regulatory agencies, including 22 conducted by the U.S. FDA and EMA. This underscores the company's commitment to maintaining high standards in its operations.
